| HOME >> BIOLOGY >> TECHNOLOGY |
"None of the audit issues raised by afssaps was a result of product contamination or deficiencies in the tissue grafts," said Greg Cannedy, Vice President of Regulatory Affairs at Osteotech. "Our goal was to resolve the deficiencies cited in the afssaps audit report as soon as possible. With this decision by afssaps we continue to build upon our excellent safety track record. Osteotech remains dedicated to providing proven technology and safe products that patients and surgeons can rely on to deliver superior outcomes to the patient."
About Osteotech
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at www.osteotech.com.
Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and
'/>"/>
| SOURCE Osteotech, Inc. Copyright©2009 PR Newswire. All rights reserved |